News | PET Imaging | March 29, 2016

New PET Imaging Technology Could Improve Cancer Treatment Response

New method could lead to better therapies for many deadly cancers

PET imaging, cancer treatment, UCLA study, Caius Radu, dCK

March 29, 2016 —A promising new discovery by University of California Los Angeles (UCLA) scientists could lead to a new method of identifying cancer patients that express high levels of an enzyme and are more likely to respond to cancer treatments.

Decades of significant advances and improvements in positron emission tomography (PET) imaging technology have led to the detection of an enzyme in humans that plays a significant role in DNA formation, the building blocks of life. The enzyme, called deoxycytidine kinase (dCK), was previously found to be highly expressed in acute leukemia cells and in activated lymphocytes and controls a critical step in the nucleoside salvage pathway, an important therapeutic and PET imaging target in cancer.

The study was published online March 28 in the journal Proceedings of the National Academy of Sciences of the United States of America.

In a seven-year study, a team of UCLA researchers led by Caius Radu, M.D., a UCLA Jonsson Comprehensive Cancer Center member and a professor in the Department of Molecular and Medical Pharmacology, developed a highly sophisticated PET probe called [18F]CFA that is capable of detecting dCK activity in humans for the first time.

"The quality of the images is much better," said Radu. "We are able to clearly see tissues, including tumor tissues, with high dCK activity that we haven't seen before in humans using any of the other probes previously developed for this enzyme."

PET is a noninvasive imaging technology that uses a radioactive substance, called PET probe, to look for disease in the body and it also shows how organs and tissues are functioning. Until recently, PET technology was only able to clearly detect dCK in mice due to metabolic instability of the previous probes and cross-reactivity with a dCK-related enzyme in humans.

The dCK enzyme plays an integral role in allowing drugs such as Clofarabine, Cytarabine and Fludarabine to treat certain types of leukemia and others like Gemcitabine to treat breast, ovarian, non-small cell lung and pancreatic cancers.

"This enzyme is essential for the therapeutic activity of an entire class of anticancer drugs and even for some antiviral drugs," said Radu, who is also a member of the UCLA Broad Stem Cell Research Center. "It can take an inactive drug and activate it. If you trick a cancer cell or virus to activate the drug, it would be toxic for the cancer cell or viral genome."

Since activated immune cells increase their expression of the dCK enzyme, [18F]CFA could also be used to monitor the effectiveness of immunotherapeutic interventions, said Radu.

The researchers hope to begin clinical trials with the [18F]CFA in the near future. Radu and his colleagues will eventually seek an approval by the U.S. Food & Drug Administration.

Radu and his team are co-founders of Sofie Biosciences and they are the inventors of [18F]CFA and analogs, which were patented by the University of California and have been licensed to Sofie Biosciences. University of California also patented additional intellectual property for small molecule dCK inhibitors.

For more information: www.pnas.org

Related Content

Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
Bennett S. Greenspan, M.D.

Bennett S. Greenspan, M.D.

News | Molecular Imaging | June 13, 2017
Bennett S. Greenspan, M.D., MS, FACNM, FACR, professor of radiology at the Medical College of Georgia, Augusta...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
MIM Software Inc. Announces Updates to MIM Encore
Technology | Remote Viewing Systems | May 31, 2017
MIM Software Inc. recently announced significant updates to its MIM Encore solution for viewing nuclear medicine images...
News | Enterprise Imaging | May 25, 2017
At the 2017 annual meeting of the Society for Imaging Informatics in Medicine (SIIM), June 1-3 in Pittsburgh, Konica...
Overlay Init